Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Rocket Pharmaceuticals, Inc. (RCKT)
Price$3.86Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $105.4M | $57.9M | $53.3M | $14.9M | $6.0M | $12.6M | $5.6M |
| Operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M | $134.3M | $76.2M | $71.2M | $19.8M | $7.6M | — | — |
| Operating income | −$231.7M | −$273.2M | −$259.7M | −$224.3M | −$167.2M | −$134.3M | −$76.2M | −$71.2M | −$19.8M | −$7.6M | −$20.4M | −$7.7M |
| EBITDA | −$222.8M | −$266.0M | −$254.8M | −$220.4M | −$164.0M | −$133.2M | −$75.7M | −$70.8M | −$19.6M | −$7.5M | −$20.4M | −$7.7M |
| Net income | −$223.1M | −$258.7M | −$245.6M | −$221.9M | −$169.1M | −$139.7M | −$77.3M | −$74.5M | −$19.6M | −$7.6M | −$68.0M | −$9.5M |
| Basic EPSper basic share | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | -$1.89 | -$2.88 | -$1.11 | -$14.88 | -$54.08 |
| Diluted EPSper diluted share | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | -$1.89 | -$2.88 | -$1.11 | -$14.88 | -$54.08 |
Owners
Reported shareholders
≈16.65%of listed shares
WONG RODERICK18.24M shares · Jun 18, 2025
View holders
| Holder | % owned |
|---|---|
WONG RODERICK | ≈16.65%18.24M shares |
RTW INVESTMENTS, LP | 16.15%17.69M shares |
BlackRock, Inc. | 9.06%9.92M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.30%5.81M shares |
CITIGROUP INC | 4.44%4.87M shares |
MARSHALL WACE, LLP | 3.68%4.03M shares |
MILLENNIUM MANAGEMENT LLC | 3.65%4M shares |
Newtyn Management, LLC | 3.65%4M shares |
MAVERICK CAPITAL LTD | 3.58%3.92M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.45%3.78M shares |
AQR CAPITAL MANAGEMENT LLC | 3.09%3.39M shares |
GOLDMAN SACHS GROUP INC | 2.59%2.83M shares |
Monaco Asset Management SAM | 2.26%2.48M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.16%2.37M shares |
FEDERATED HERMES, INC. | 2.10%2.3M shares |
JPMORGAN CHASE & CO | 1.82%1.99M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.80%1.97M shares |
STATE STREET CORP | 1.66%1.82M shares |
Shah Gaurav | ≈1.34%1.47M shares |
DIMENSIONAL FUND ADVISORS LP | 1.03%1.13M shares |
Percentages use 109.54M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 | Shah GauravCEO | SellCommon Stock | 55.7K | $3.09 | $172.1K | 1.06M |
| May 19, 2026Form 4 | Shah GauravCEO | SellCommon Stock | 2.4K | $3.01 | $7.3K | 1.04M |
| May 19, 2026Form 4 | Wilson MartinGeneral Counsel | SellCommon Stock | 662 | $3.01 | $2.0K | 678.0K |
| May 19, 2026Form 4 | Militello JohnSee Remarks | SellCommon Stock | 384 | $3.01 | $1.2K | 89.8K |
| May 13, 2026Form 4 | Wilson MartinGeneral Counsel | SellCommon Stock | 3.4K | $3.61 | $12.1K | 678.6K |